Biocartis, AstraZeneca to develop CDx for EGFR TKI treatment

By LabPulse.com staff writers

June 22, 2022 -- Biocartis has signed a deal to codevelop a companion diagnostic test (CDx) with AstraZeneca for the pharma firm’s epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) treatment Tagrisso (osimertinib).

The firms aim to obtain applicable premarket notification or approval from the U.S. Food and Drug Administration (FDA) for a CDx test on Biocartis' fully automated molecular Idylla platform.

They will codevelop Idylla EGFR CDx assay to aid in identifying patients with non-small cell lung cancer (NSCLC) who may respond to treatment with Tagrisso.

Biocartis will seek to validate the use of less invasive cytology samples, such as fine needle aspirates, in addition to formalin-fixed paraffin-embedded (FFPE2) tissue for use with the new assay.

AstraZeneca, G42 Healthcare aim to collaborate
Abu Dhabi-based G42 Healthcare has signed a letter of intent with AstraZeneca with the aim of expanding their collaboration into diagnostics and clinical...
Grail, AstraZeneca to collaborate on companion diagnostic tests
Grail on Thursday announced its strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s...
Saga inks assay development deal with AstraZeneca
Swedish liquid biopsy and genomic testing provider Saga Diagnostics is developing new digital polymerase chain reaction assays for AstraZeneca.
Thermo Fisher, AstraZeneca to develop NGS companion diagnostics
Thermo Fisher Scientific and AstraZeneca plan to co-develop companion diagnostics based on next-generation sequencing (NGS) to support targeted therapies.
Biocartis signs deal with Covance for Idylla molecular testing
Belgian molecular diagnostics developer Biocartis Group has signed a deal to make its Idylla molecular testing technology available to customers of Covance...

Copyright © 2022 LabPulse.com

Last Updated mp 6/22/2022 1:14:19 PM